Business Context and Reporting Period
The filing identifies the registrant as Ambac Financial Group, Inc., not Octave Specialty Group Inc. It is an unaudited Form 10-Q for the quarter ended September 30, 2014, filed November 10, 2014. Ambac is a financial-services holding company with Financial Guarantee and Financial Services segments. Its core businesses are in runoff following significant insured-portfolio losses and the Company’s emergence from Chapter 11 on May 1, 2013.
Because fresh-start accounting created a new reporting entity, Successor Ambac periods beginning May 1, 2013 are not fully comparable with Predecessor Ambac periods. The filing states that there is substantial doubt about Ambac’s ability to continue as a going concern, although the financial statements were prepared on a going-concern basis.
Key Financial Metrics
| Metric | Q3 2014 | Comparable Q3 2013 |
|---|---|---|
| Net premiums earned | $64.8 million | $70.9 million |
| Net investment income | $83.6 million | $52.1 million |
| Total revenues before expenses and reorganization items | $155.3 million | $171.7 million |
| Losses and loss expenses | Benefit of $28.7 million | Benefit of $154.3 million |
| Pre-tax income from continuing operations | $84.8 million | $231.6 million |
| Net income attributable to common shareholders | $82.5 million | $231.0 million |
| Diluted earnings per share | $1.77 | $4.98 |
| Operating Earnings, non-GAAP | $142.7 million | $193.4 million |
For the nine months ended September 30, 2014, Successor Ambac reported net premiums earned of $212.4 million, net investment income of $234.5 million, pre-tax income of $33.7 million, net income attributable to common shareholders of $30.5 million, and Operating Earnings of $206.0 million. The filing does not present a meaningful full nine-month comparable period because 2013 includes separate Successor and Predecessor periods.
| Balance-sheet metric | September 30, 2014 | December 31, 2013 |
|---|---|---|
| Total assets | $26.59 billion | $27.09 billion |
| Total liabilities | $25.34 billion | $26.11 billion |
| Total stockholders’ equity | $1.25 billion | $978.4 million |
| Ambac stockholders’ equity | $975.7 million | $703.0 million |
| Cash and cash equivalents | $43.3 million | $77.4 million |
| Long-term debt | $1.22 billion | $963.2 million |
| Loss and loss expense reserves | $6.00 billion | $5.97 billion |
Cash provided by operating activities for the first nine months of 2014 was $258.4 million. Investing activities used $316.7 million, primarily reflecting bond purchases and collateral-related movements. Financing activities provided $24.3 million, including $224.3 million of proceeds from the sale of junior surplus notes, partly offset by $200.0 million of investment-agreement payments. Cash and cash equivalents declined by $34.0 million to $43.3 million.
Ambac’s non-GAAP Adjusted Book Value was negative $64.6 million at September 30, 2014, compared with revised negative $49.9 million at December 31, 2013. The filing states that the 2013 Adjusted Book Value was revised by $230.8 million to correct the treatment of future installment premiums related to an Ambac UK exposure.
Material Changes Versus the Prior Comparable Period
- Quarterly net income attributable to common shareholders decreased to $82.5 million from $231.0 million, primarily because the prior-year period benefited from substantially larger gains on VIEs, credit derivatives and loss-reserve development.
- Net investment income increased by $31.5 million to $83.6 million, reflecting investment in Ambac-wrapped securities, higher yields associated with revised rehabilitation-plan cash-flow assumptions, and income on other investments.
- The loss-and-loss-expense benefit declined to $28.7 million from $154.3 million. Q3 2014 included $51.7 million of interest accrued on Deferred Amounts under the amended rehabilitation plan.
- Derivative product revenue changed from a $12.4 million gain to a $15.7 million loss, principally due to mark-to-market effects from falling interest rates.
- Income from variable interest entities declined to $9.1 million from $55.1 million in the quarter and was a $34.6 million loss for the nine months, largely reflecting changes in VIE fair values and credit valuation adjustments.
- Guaranteed net par outstanding declined to $157.4 billion from $179.1 billion at December 31, 2013, reflecting portfolio runoff, claims, repayments and other reductions.
- Non-VIE investments increased to $7.06 billion from $6.52 billion, while VIE assets and liabilities declined. Stockholders’ equity increased primarily from comprehensive income, including unrealized investment gains.
- Net credit-derivative notional outstanding declined to $2.0 billion from $2.8 billion, and the related net fair-value liability declined to $82.8 million from $94.3 million.
Guidance, Outlook, Risks and Unusual Items
- Rehabilitation-plan cash requirements: The amended Segregated Account Rehabilitation Plan increased initial interim cash payments on permitted claims from 25% to 45% beginning July 21, 2014. The Rehabilitator estimated equalizing Deferred Amount payments of approximately $1.14 billion on December 22, 2014.
- Surplus-note redemptions: Early redemption of certain Segregated Account and Ambac Assurance surplus notes, including accrued interest, was estimated at approximately $413.6 million. The filing states that total related fourth-quarter cash outflows were expected to exceed $1.5 billion.
- Liquidity: Ambac Assurance’s ability to pay dividends to the parent is highly restricted and considered highly unlikely in the foreseeable future. Parent liquidity depends principally on cash and investments, expense-sharing and other arrangements, potential NOL-related payments, and the uncertain value of an Owner Trust Certificate received in the junior-surplus-note transaction.
- Going concern: Management concluded that substantial doubt exists about Ambac’s ability to continue as a going concern because the Rehabilitator controls significant aspects of the Segregated Account and may act without regard to Ambac’s securityholders.
- Junior surplus-note monetization: On August 28, 2014, Ambac sold $350.0 million face amount of junior surplus notes for $224.3 million in cash and a $74.8 million face-value Owner Trust Certificate. The related third-party notes mature in 2039 and accrue interest at 5.1%; payments to Ambac on the certificate are subordinate and uncertain.
- Reserve uncertainty: Management identified reasonably possible additional loss reserves of approximately $126 million for RMBS, $511 million for student loans, $1.68 billion for public finance, and $556 million for other credits including Ambac UK, under specified stress scenarios. These are not stated as expected losses.
- Subrogation recoveries: Recorded RMBS representation-and-warranty recoveries were approximately $2.21 billion before reinsurance. Recoverability depends on litigation, sponsor solvency, contractual interpretations and regulatory oversight.
- Regulatory and operating risks: Ambac Assurance had statutory policyholder surplus of $897.7 million, above the $100 million minimum surplus amount. Ambac UK nevertheless had a regulatory capital shortfall of approximately £444.8 million at September 30, 2014.
- Legal matters: The filing describes ongoing litigation involving municipalities, RMBS counterparties and other parties. Accruals for matters meeting the probable-and-estimable threshold were not material, but adverse outcomes in other matters could materially affect results, liquidity or financial position.
- Controls: Management concluded that disclosure controls and procedures were effective as of September 30, 2014, with no material change in internal control over financial reporting during the quarter.
Most Important Facts for Investors to Verify
- Confirm that the intended issuer is Ambac Financial Group, Inc.; the supplied metadata names a different company.
- Assess the impact and funding of the expected fourth-quarter 2014 Deferred Amount payments and surplus-note redemptions exceeding $1.5 billion.
- Review the going-concern disclosure and the extent to which the Rehabilitator controls claim payments, asset remediation and surplus-note payments.
- Evaluate the quality and collectability of the approximately $2.21 billion RMBS subrogation recovery estimate and other recoveries.
- Reconcile GAAP net income with Operating Earnings and Adjusted Book Value, particularly the effects of VIE consolidation, fair-value marks, credit valuation adjustments and insurance-intangible amortization.
- Monitor stress exposure in public finance, student loans, RMBS, Puerto Rico-related credits and Ambac UK.
- Review liquidity, collateral requirements, investment-agreement withdrawal risk and potential derivative termination payments.
- Confirm the status of the Ambac UK regulatory capital shortfall, litigation appeals and any subsequent amendments to the Segregated Account Rehabilitation Plan.